4//SEC Filing
Azamian Bobak R. 4
Accession 0001819790-25-000046
CIK 0001819790other
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 9:40 PM ET
Size
12.6 KB
Accession
0001819790-25-000046
Insider Transaction Report
Form 4
Azamian Bobak R.
DirectorPresident/CEO and Board Chair
Transactions
- Exercise/Conversion
Restricted Stock Units
2025-03-15−11,299→ 11,300 total→ Common Stock (11,299 underlying) - Exercise/Conversion
Common Stock
2025-03-15+51,395→ 77,851 total - Exercise/Conversion
Restricted Stock Units
2025-03-15−23,121→ 69,364 total→ Common Stock (23,121 underlying) - Exercise/Conversion
Restricted Stock Units
2025-03-15−16,975→ 33,950 total→ Common Stock (16,975 underlying)
Holdings
- 830,106(indirect: By Trust)
Common Stock
Footnotes (6)
- [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
- [F2]The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
- [F3]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
- [F4]RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025 and 2026, subject to the Reporting Person's continuous service.
- [F5]RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
- [F6]RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.
Documents
Issuer
Tarsus Pharmaceuticals, Inc.
CIK 0001819790
Entity typeother
Related Parties
1- filerCIK 0001827672
Filing Metadata
- Form type
- 4
- Filed
- Mar 17, 8:00 PM ET
- Accepted
- Mar 18, 9:40 PM ET
- Size
- 12.6 KB